ReviewFrontiers in immunology2016
Is It worth Considering Circulating microRNAs in Multiple Sclerosis?
Review in Frontiers in immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04300543 (MicroRNA-150 and microRNA-155 as Molecular Biomarkers in Multiple Sclerosis), which is not on this map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
MicroRNA-150 and microRNA-155 as Molecular Biomarkers in Multiple Sclerosis
Who cites it
25 citing papers in PubMed, 44 citations in OpenAlex.
- Extracellular RNAs as Messengers and Early Biomarkers in Neurodegeneration.International journal of molecular sciences · 2025Review
- Multiple sclerosis pathophysiology: a comprehensive review of genetic, environmental, and immunological drivers.Inflammopharmacology · 2025Review
- Exosomal microRNAs as Early Transition Biomarkers from Recurrent-Remissive to Secondary Progressive Multiple Sclerosis.International journal of molecular sciences · 2025Review
- TNFα protein, DNA methylation, mRNA and miRNA expression evaluation in multiple sclerosis.Frontiers in molecular biosciences · 2025Article
- Stem Cell-Derived Exosomal MicroRNAs as Novel Potential Approach for Multiple Sclerosis Treatment.Cellular and molecular neurobiology · 2024Review
- Mesenchymal Stem Cell-Derived Extracellular Vesicles: An Emerging Diagnostic and Therapeutic Biomolecules for Neurodegenerative Disabilities.Biomolecules · 2023Review
- Emerging role of extracellular vesicles in multiple sclerosis: From cellular surrogates to pathogenic mediators and beyond.Journal of neuroimmunology · 2023Review
- The role of microRNAs involved in the disorder of blood-brain barrier in the pathogenesis of multiple sclerosis.Frontiers in immunology · 2023Review
- miRNA Signature in CSF From Patients With Primary Progressive Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2023Article
- MicroRNAs as a possible biomarker in the treatment of multiple sclerosis.IBRO neuroscience reports · 2022Review
- Extracellular Vesicles, Stem Cells and the Role of miRNAs in Neurodegeneration.Current neuropharmacology · 2022Review
- Description of a CSF-Enriched miRNA Panel for the Study of Neurological Diseases.Life (Basel, Switzerland) · 2021Article
- Extracellular vesicles (exosomes and ectosomes) play key roles in the pathology of brain diseases.Molecular biomedicine · 2021Review
- The Role of Extracellular Vesicles in Demyelination of the Central Nervous System.International journal of molecular sciences · 2020Review
- miRNA profile is altered in a modified EAE mouse model of multiple sclerosis featuring cortical lesions.eLife · 2020Article
- Immune and central nervous system-related miRNAs expression profiling in monocytes of multiple sclerosis patients.Scientific reports · 2020Article
- Potential roles of extracellular vesicles in the pathophysiology, diagnosis, and treatment of autoimmune diseases.International journal of biological sciences · 2020Review
- Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-Remitting Multiple Sclerosis.Frontiers in immunology · 2020Article
- Decoding the Role of Platelets and Related MicroRNAs in Aging and Neurodegenerative Disorders.Frontiers in aging neuroscience · 2019Review
- Dietary Modulation of Intestinal Microbiota: Future Opportunities in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis.Frontiers in microbiology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
New evidence has highlighted that miRNA production and trafficking can be dysregulated in both autoimmmune and neurological disorders. Multiple sclerosis (MS) in particular is an autoimmune pathology leading to neurodegeneration. Profiling studies performed on cells derived from MS patients have described a dysregulated network of miRNAs in both immune and neural cells. Interestingly, new evidence has emerged showing that circulating miRNAs are also dysregulated in MS body fluids, including plasma/serum and cerebrospinal fluid. This review summarizes the current scientific theories on the function of this altered circulating miRNA network. It builds up new insights about miRNA transfer mechanisms including extracellular vesicle trafficking involved in cell-to-cell communication and the possible physiopathological functions of these transfers in MS. Finally, this review proposes that monitoring altered miRNA expression levels could serve as a potential biomarker read-out of MS subtype and severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.